Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function
“…This was in accordance with results from our previous study [7]. In this study, no bradycardia or other b-blocking effects were observed.…”
Section: Discussionsupporting
confidence: 94%
“…Average steady-state concentrations and the AUC between dosing intervals in the present study in unfasted horses were about 50% lower than the values predicted by the previous study. Time to reach maximal plasma concentrations ranged from 1.47 to 2.56 h, compared with 1 h in fasted horses [7], indicating that also the rate of absorption is decreased when administering the drug with feed. These differences illustrate the effect of feeding on the bioavailability of sotalol.…”
Section: Discussionmentioning
confidence: 96%
“…administration in the horse, using a full sampling protocol for each subject [7]. For our study, we chose to limit the number of blood samples drawn from each horse for ethical concerns as well as practical feasibility.…”
Section: Discussionmentioning
confidence: 99%
“…Sotalol plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method, as described before [7]. Sotalol plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method, as described before [7].…”
Section: Sotalol Plasma Analysismentioning
confidence: 99%
“…Fractional shortening, left ventricular pre-ejection period, left ventricular pre-ejection time and pre-ejection period to ejection time ratio were measured as described elsewhere at a heart rate (HR) between 32 and 40 beats/min [7,9]. A modified base-apex ECG was recorded simultaneously.…”
Sotalol at a dose of 2, 3 and 4 mg/kg bwt PO bid increases the QT interval and ERP and might be a useful drug for long-term anti-arrhythmic therapy in horses.
“…This was in accordance with results from our previous study [7]. In this study, no bradycardia or other b-blocking effects were observed.…”
Section: Discussionsupporting
confidence: 94%
“…Average steady-state concentrations and the AUC between dosing intervals in the present study in unfasted horses were about 50% lower than the values predicted by the previous study. Time to reach maximal plasma concentrations ranged from 1.47 to 2.56 h, compared with 1 h in fasted horses [7], indicating that also the rate of absorption is decreased when administering the drug with feed. These differences illustrate the effect of feeding on the bioavailability of sotalol.…”
Section: Discussionmentioning
confidence: 96%
“…administration in the horse, using a full sampling protocol for each subject [7]. For our study, we chose to limit the number of blood samples drawn from each horse for ethical concerns as well as practical feasibility.…”
Section: Discussionmentioning
confidence: 99%
“…Sotalol plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method, as described before [7]. Sotalol plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method, as described before [7].…”
Section: Sotalol Plasma Analysismentioning
confidence: 99%
“…Fractional shortening, left ventricular pre-ejection period, left ventricular pre-ejection time and pre-ejection period to ejection time ratio were measured as described elsewhere at a heart rate (HR) between 32 and 40 beats/min [7,9]. A modified base-apex ECG was recorded simultaneously.…”
Sotalol at a dose of 2, 3 and 4 mg/kg bwt PO bid increases the QT interval and ERP and might be a useful drug for long-term anti-arrhythmic therapy in horses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.